Naveen K. Dakappagari, Ph.D.
Affiliations: | 2001 | Ohio State University, Columbus, Columbus, OH |
Area:
Immunology, OncologyGoogle:
"Naveen Dakappagari"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Pravin Kaumaya | grad student | 2001 | Ohio State | |
| (Evaluation of chimeric B-cell epitope vaccines of HER -2: Application to cancer patients.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mora J, Palmer R, Wagner L, et al. (2024) 2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization). Bioanalysis |
| Corsaro B, Yang TY, Murphy R, et al. (2021) 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). Bioanalysis |
| Spitz S, Zhang Y, Fischer S, et al. (2021) 2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( - Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis |
| Khunger A, Sarikonda G, Tsau J, et al. (2021) Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma. Translational Oncology. 14: 101014 |
| Siska PJ, Johnpulle RAN, Zhou A, et al. (2017) Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. Oncoimmunology. 6: e1305535 |
| Pahuja A, Saci A, Sarikonda S, et al. (2014) Abstract LB-96: A novel blood preservation system to study oncogenic signaling pathway biomarkers by flow cytometry in leukemia/lymphoma clinical trials Cancer Research. 74 |
| Tangri S, Dakappagari N, Estrellado A, et al. (2009) CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas. Blood. 114: 1953-1953 |
| Kretz-Rommel A, Qin F, Dakappagari N, et al. (2008) Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy Journal of Immunology. 180: 699-705 |
| Kretz-Rommel A, Qin F, Dakappagari N, et al. (2007) In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. Journal of Immunotherapy. 30: 715-726 |
| Kretz-Rommel A, Qin F, Dakappagari N, et al. (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 178: 5595-605 |